Background Most people infected with HIV-1 are dually infected with herpes simplex virus type 2. Daily suppression of this herpes virus reduces plasma HIV-1 concentrations, but whether it delays HIV-1 disease progression is unknown. We investigated the eff ect of aciclovir on HIV-1 progression.
Introduction
Recent expansion of access to antiretroviral therapy has had a large eff ect on disease progression and mortality of people with HIV-1 infection in resource-poor countries. However, only a third of people with HIV-1 who meet international antiretroviral therapy initiation guidelines are given these drugs. 1 The number of people needing antiretroviral therapy will continue to grow, despite constraints on antiretroviral programmes and resources-especially if increased CD4 thresholds are adopted for initiation of antiretroviral therapy (eg, 350 cells per μL). Moreover, most people infected with HIV-1 worldwide have counts that are higher than the therapy starting thresholds of 200 or 350 CD4 cells per μL. Thus, low-cost interventions to slow HIV-1 disease progression are needed for those who do not meet present antiretroviral initiation guidelines.
Infection with herpes simplex virus type 2 is the most common cause of genital ulcer disease worldwide. Seroprevalence of this virus in people with HIV-1 ranges from 70% to more than 90%.
2 Reactivation of this herpes virus is common and often asymptomatic in HIV-1-infected people, occurring on about a third of days. 3 Plasma and genital HIV-1 concentrations increase during reactivation, [4] [5] [6] [7] [8] suggesting that herpes reactivation enhances HIV-1 replication, possibly through binding of herpes simplex virus proteins to the HIV-1 long-terminal repeat, raising concentrations of pro-infl ammatory cytokines, or through infi ltration of HIV-1 target cells in the genital tract. [9] [10] [11] In view of the strong relation between raised plasma HIV-1 concentrations and increased speed of HIV-1 disease progression, 12,13 suppression of herpes virus type 2 has been regarded as a potential strategy to reduce HIV-1 concentrations and slow its progression. Researchers of fi ve randomised trials [14] [15] [16] [17] [18] of people dually infected with these viruses who were not taking anti retroviral therapy reported that daily herpes suppressive therapy with aciclovir or valaciclovir for 8-12 weeks reduced plasma HIV-1 concentrations by 0·25-0·5 log 10 copies per μL.
We undertook a multicentre trial of daily suppression of herpes simplex virus type 2 with aciclovir in Africans who were dually infected with HIV-1 and herpes simplex virus type 2 to assess the effi cacy of suppressive aciclovir on measures of HIV-1 disease progression.
Methods

Participants
Heterosexual couples who were discordant for HIV-1 infection were recruited at sites in southern Africa (Gaborone Botswana; Cape Town, Orange Farm, and Soweto South Africa; and Kitwe, Lusaka, and Ndola Zambia) and east Africa (Eldoret, Kisumu, Nairobi, and Thika, Kenya; Kigali Rwanda; Moshi Tanzania; and Kampala Uganda) between Nov 23, 2004 and May 16, 2007 . Eligible HIV-1 infected partners were 18 years or older, seropositive for HIV-1 and herpes simplex virus type 2, and had a CD4 cell count of 250 cells per μL or higher. We excluded those who, at enrolment, had an AIDS-defi ning diagnosis, reported taking antiretroviral therapy, had previous adverse reactions to aciclovir or planned use of antivirals, or were pregnant. 19 The University of Washington Human Subjects Review Committee and ethical review committees at each local institution, collaborating organisation, and national regulatory board approved the study protocol. All participants provided written informed consent.
Procedures
The Partners in Prevention HSV/HIV Transmission Study was a randomised, double-blind, placebocontrolled trial of twice daily aciclovir 400 mg for herpes simplex virus type 2 suppression, given to the partner with dual HIV-1 and herpes type 2 infection within heterosexual HIV-1 serodiscordant couples (ie, one partner was HIV-1 infected and the other was not). The primary aim of the trial was to measure effi cacy of aciclovir on reduction of HIV-1 transmission. As reported elsewhere, [19] [20] [21] aciclovir did not reduce HIV-1 transmission within couples, despite reduction of herpes virus type-2-positive genital ulcer disease by 73% and HIV-1 plasma concentrations by 0·25 log 10 copies per μL. 19 Study procedures have been described elsewhere. [19] [20] [21] After the trial was underway, investigators identifi ed that the number of clinical events related to HIV-1 disease (eg, CD4 cell count falling to <200 cells per μL and initiation of antiretroviral therapy) was suffi cient to warrant an analysis of HIV-1 disease progression by study group. The Data and Safety Monitoring Board accepted an addendum to the statistical analysis plan describing this analysis.
Participants were followed up every month for up to 24 months after enrolment. At each visit, a 1-month supply of study drug and adherence counselling was provided. Adherence to study drug was assessed by pill count and self-report, defi ned as 100% adherence or less than 100%. Women were tested for pregnancy every 3 months and when they reported missed menses. Those who became pregnant had their study drug interrupted for the duration of pregnancy, and were referred to local antenatal clinics for prevention of mother-to-child transmission (PMTCT) services. CD4 cell counts were measured twice per year and clinical assessment was undertaken every 3 months. Participants meeting national CD4 cell count and clinical criteria for anti retroviral therapy initiation during follow-up were off ered this therapy through referral to local clinics or at the study site. Cause of death of participants who died during follow-up was obtained from family members and medical records, when available. Participants received intensive risk-reduction counselling (both individually and as a couple), free condoms, and treatment of sexually transmitted infections at enrolment and during follow-up visits. Follow-up was continued for participants who reached an HIV-1 disease-progression endpoint. Figure 1: Trial profi le HSV2=herpes simplex virus type 2. ART=antiretroviral therapy. *HSV2 seropositivity at enrolment confi rmed by western blot (WB). †Numerator includes attended visits only. Denominator includes all expected visits including staged site close-out. During follow-up, three participants were dispensed with a drug kit for the incorrect randomisation group; follow-up time has been censored at the visit when this occurred.
As previously described, 19, 20 serological tests for HIV-1 were by dual rapid tests with confi rmatory EIA, and for herpes simplex virus type 2 were by HerpeSelect-2 EIA (Focus Technologies, Cypress, CA, USA), with an index value of 3·5 or higher to improve test specifi city. [22] [23] [24] Serostatus for both infections was confi rmed in batched testing at the University of Washington by western blot with enrolment sera, with people who were not confi rmed by western blot excluded from analysis. 20 CD4 testing was undertaken at study sites with standard fl ow cytometry (BD Biosciences, San Jose, CA, USA).
Randomisation and masking
The randomisation method was developed and implemented by the study statistician, JPH, and used block sizes of 4, 6, 8, and 10, stratifi ed by site. We used the randomisation list to assemble sequentially numbered, identical sealed kits containing, in a 1:1 ratio, suffi cient aciclovir (400 mg, orally, twice daily) or matched placebo (Ranbaxy Laboratories, Haryana, India) for the entire study period. At enrolment, HIV-1-infected partners were assigned the next sequentially numbered kit. Participants were instructed to take one tablet in the morning and one in the evening, and to double the next dose if a dose was missed. Investigators (apart from an unmasked statistician and two data managers from the coordinating centre) remained masked to randomisation assignments throughout the study follow-up.
Study endpoints
Three measures to assess the eff ect of aciclovir on HIV-1 disease progression were identifi ed before study unblinding: (1) CD4 cell counts falling to fewer than 200 cells per μL, (2) fi rst reported use of antiretroviral therapy (excluding antiretrovirals used for PMTCT), and (3) death from non-trauma causes. The primary analysis was a composite endpoint defi ned as the fi rst occurrence of any of these three outcomes; only the fi rst HIV-1 diseaseprogression endpoint was included in the primary composite endpoint if a participant had more than one (eg, CD4 cell count falling to fewer than 200 cells per μL after antiretroviral therapy was initiated).
Similar composite measures have been used as outcomes in previous studies [25] [26] [27] of antiretroviral therapy, and have been proposed as outcomes for trials of preventive HIV-1 vaccines that might alter viral load and disease progression. In secondary analyses, we assessed every outcome measure separately. In an exploratory analysis after unblinding of study randomisation, we investigated the fall in CD4 cell count to fewer than 350 cells per μL in those with counts of 350 cells per μL or higher at study entry to refl ect changes in antiretroviral initiation guidelines. 28 Because of the eff ect of anti retroviral therapy on reduction of CD4 cell counts and mortality, participants starting antiretroviral therapy (for any reason) were censored thereafter from the risk pool for any analyses of the death or CD4 endpoints.
Statistical analysis
For statistical analyses, we used SAS 9.2. All analyses were by intention to treat. We used Cox proportional hazards regression models, stratifi ed by site, to compare time to occurrence of HIV-1 disease progression outcomes between the two intervention groups, and applied the Efron method for handling ties. 29 We used the Kaplan-Meier method to estimate and plot by intervention group the cumulative probability of reaching the study endpoint. Additionally, we undertook Cox proportional hazards analyses for the composite disease-progression endpoint for prespecifi ed subgroups that were defi ned by the following baseline characteristics: sex, HIV-1 plasma-viral load, and CD4 cell count. Tests for diff erential treatment eff ects across subgroups were based on likelihood ratio comparisons between models with and without appropriate interaction terms.
We calculated adherence to study drug as the product of the proportion of dispensed drug taken and the proportion of visits at which the drug was dispensed. Among 91·5% of study visits for which the proportion of dispensed drug taken could be ascertained, 99·2% were established by pill count from returned study drug bottles; in the remaining 0·8% of visits that did not have pill counts but in which participants self-reported adherence, the proportion of study drug taken was
Age ( 100%. This adherence measure assesses study-drug coverage during follow-up and accounts for drug not dispensed (mainly for missed visits and pregnancy). Participants contributed to adherence data until the time of the composite endpoint. With a postrandomisation subgroup analysis, we assessed the eff ect of study-drug coverage over time on the risk of development of the composite primary endpoint. For this analysis, we analysed drug coverage averaged for every 3 months of study follow-up as a time-varying covariate, and categorised coverage as less than 75%, 75-89%, or 90% or higher. We calculated the number of participants that would need treatment with aciclovir to prevent one event in 1 year (the number needed to treat), based on survival for a year in the placebo group (calculated from the mean hazard during all follow-up) and the hazard ratio (HR) comparing aciclovir to placebo. 30 Because the median time to each outcome was not attained during study follow-up, we projected the median times, assuming a constant hazard in both groups.We undertook a sensitivity analysis to assess the possible eff ect of missing follow-up data on our primary analysis. A sensitivity-adjusted RR (sRR) was calculated as in which, pyrs is the number of observed person-years in the group (A for aciclovir and P for placebo), myrs is the number of missing person-years in the group, and α is the relative incidence during the missing personyears compared with the observed person-years. We allowed α to vary from 0·75 to 1·50 in each group. We also calculated a sensitivity-adjusted p value by division of the log (sRR) by the SE of the estimated log HR from the primary analysis and comparison with a standard normal table.
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The authors designed the study and wrote the protocol, had full access to the raw data, (pyrs(A)+myrs(A)×α(A))/(pyrs(A)+myrs(A)) (pyrs(P)+myrs(P)×α(P))/(pyrs(P)+myrs(P)) ×RR sRR= NNT=number needed to treat. ART=antiretroviral therapy.*Number of participants who had at least one follow-up visit with endpoint assessed. †Number of people co-infected with HIV-1 and herpes simplex virus type 2 needed to treat with aciclovir 400 mg twice daily for 1 year to prevent one person reaching the HIV-1 disease-progression endpoint. ‡Excluding ART initiated for prevention of mother-to-child transmission (PMTCT). §Censored at fi rst report of ART use (other than short-course PMTCT). ¶Assessed only for those who had CD4 cell counts of 350 cells per μL or higher at baseline; this endpoint was added post hoc after study unblinding. Participants were censored upon reaching primary composite HIV-1 disease progression endpoint. Adherence data were missing for 8·5% of 3-monthly visits. Visit-specifi c data were calculated as the product of overall dispensed drug taken and proportion of participants to whom drug was dispensed. Table 2 : Study-drug coverage during follow-up by study group* undertook all analyses, wrote the manuscript, and had fi nal responsibility for the decision to submit for publication.
Results Figure 1 shows the trial profi le. Baseline demographic and clinical characteristics were similar between the two study groups (table 1) . 68% of participants were women. The median baseline CD4 cell count was 462 cells per μL (IQR 347-631) and for HIV-1 plasma RNA was 4·1 log 10 copies per μL (3·4-4·7). Most participants had asymptomatic HIV-1 disease, with 5% or fewer reporting pneumonia, tuberculosis, or herpes zoster in the previous year. Retention of participants at 24 months of follow-up was 92% overall (fi gure 1). Participants contributed 4826 person-years of follow-up for analysis of the primary composite endpoint. A total of 96·3% of dispensed doses were taken and 93·7% of monthly study drug dispensed, resulting in overall drug coverage of 90·2% (table 2) . During every 3-month study follow-up, 80·8-85·3% of participants achieved 90% or higher drug coverage. During follow-up, 9·1 participants per 100 personyears had CD4 cells counts fall to fewer than 200 cells per μL, 6·7 per 100 person-years started antiretroviral therapy, excluding therapy started for PMTCT, and 1·2 per 100 person-years died. Deaths were attributed to pneumonia (n=13), tuberculosis (ten), gastrointestinal infections (seven), other infectious processes (six), malaria (fi ve), and other causes (20) . Two participants in the aciclovir group and two in the placebo group died from trauma. Six participants in the aciclovir group and fi ve in the placebo group died after starting antiretroviral therapy; these deaths were not included in the analyses. Of participants given antiretroviral therapy, the median CD4 cell count before this therapy was started was 195 cells per μL (IQR 159-246), with 34% given antiretrovirals with CD4 cell counts between 200 and 350 cells per μL and 11% with counts higher than 350 cells per μL. Table 3 and fi gure 2 show the comparison between disease progression outcomes by study group; 16% (40) fewer participants in the aciclovir group than in the placebo group reached the primary composite endpoint. Of the 608 composite endpoints, 425 (70%) had CD4 cell counts fall to fewer than 200 cells per μL, 129 (21%) were antiretroviral initiations (fi ve of whom also had a fi rst CD4 cell count <200 cells per μL at the same visit), and 54 (9%) were non-trauma deaths. When we analysed components of the composite endpoint separately, we identifi ed that aciclovir reduced risk of HIV-1 disease progression by 17-24% (corre sponding p values from 0·05 to 0·29 for the components of the primary outcome). Of 2431 participants with CD4 cell counts of 350 cells per μL or higher at enrolment, aciclovir reduced risk of progression to counts of fewer than 350 cells per μL by 19%.
We assessed the eff ect of aciclovir on the composite measure of HIV-1 disease progression within prespecifi ed subgroups that were defi ned by sex, baseline HIV-1 plasma RNA concentration, and baseline CD4 cell count (fi gure 3). We identifi ed no statistically signifi cant diff erences. The intervention seemed less eff ective in those with CD4 cell counts of less than 500 cells per μL or higher at enrolment than in those with less than 500 cells per μL, but this diff erence was not signifi cant (fi gure 3). Eff ectiveness of the intervention against HIV-1 was higher in participants with study- drug coverage of more than 90% than it was in those with less than 90% drug coverage, but this diff erence was not signifi cant. Overall, 3·3% of expected follow-up time was missing (3·2% in the aciclovir group and 3·5% in the placebo group). In sensitivity analyses, the RR for the composite primary endpoint varied between 0·81 and 0·86. Assuming that the incidence of infection during missing follow-up periods was identical in both groups and equal to the observed incidence in the placebo group, the sensitivity-adjusted RR was 0·84 (p=0·03). Assuming that the rate of HIV-1 disease progression endpoints remained constant after the 24 months of our study follow-up, we estimated that aciclovir would delay median time to the composite endpoint by 10·7 months (72·7 months in the aciclovir group vs 62·0 months in the placebo group) and median time to CD4 cell counts of fewer than 350 cells per μL by 6·3 months (35·1 months for aciclovir vs 28·8 months for placebo).
Discussion
Our results show that standard doses of aciclovir for suppression of herpes simplex virus type 2 in people infected with HIV-1 and herpes type 2 reduced the risk of HIV-1 disease progression by 16%. Fewer participants in the aciclovir group than in the placebo group had CD4 cell counts fall below 200 cells per μL (p=0·06), started antiretroviral therapy (p=0·05), or died from non-trauma-related reasons (p=0·29). Furthermore, fewer of those in the group assigned aciclovir with counts of 350 cells per μL or higher had counts fall below this concentration than did those in the placebo group (p=0·002).
Burkina Faso (women) 17 Peru (men) 18 Cross-over design Thailand (women) 16 Cross-over design Peru (women) 14 Cross-over design South Africa (women) 15 Africa (men and women) 19 Three participants died within fi rst month of study and were excluded from analysis. Data could not be classifi ed for 9% of visits because of missing data for study-drug adherence.*Number of participants with follow-up and endpoints assessed at least once during follow-up. †Study-drug coverage was averaged per quarter of follow-up and analysed as a time-dependent variable; thus, participants could have contributed to more than one category during follow-up, so total numbers of participants are not given (··).
Valaciclovir
We have previously reported 19 that aciclovir reduced HIV-1 plasma RNA by 0·25 log 10 copies per μL in this trial population. This result was similar to that reported in previous trials of short-term suppression of herpes simplex virus type 2 (1-3 months), showing a 0·25-0·5 log 10 copies per μL reduction in HIV-1 concentrations (fi gure 4).
14- 18 We infer that the reduction in HIV-1 concentrations during aciclovir suppression mediated a reduction in risk of HIV-1 disease progression. In results of a systematic review 31 of US and African observational studies, a 0·3 log 10 copies per μL reduction in plasma HIV-1 concentrations predicted a reduced risk of HIV-1 progression by 25%, lending support to our postulation. Our results show that a strategy without antiretroviral therapy (ie, with herpes type 2 suppression) that reduces plasma HIV-1 concentrations by less than do present combination antiretroviral therapy regimens can modestly delay HIV-1 disease progression.
In early studies of zidovudine monotherapy, similar reductions in HIV-1 plasma RNA 32 and a decreased risk of disease progression and mortality were reported. 33 Zidovudine eff ects waned during 3-6 months, because resistant HIV-1 variants were selected. Aciclovir is a highly specifi c chain terminator to the herpes simplex virus, needing thymidine kinase from the herpes virus for initial phosphorylation, and is preferentially incorporated by the herpes virus DNA polymerase. This mechanism, in conjunction with the reported 73% reduction in the frequency of type 2 herpes-positive genital ulcer disease in those randomised to aciclovir in our study, 19 led us to postulate that aciclovir's eff ect in reduction of HIV-1 concentrations is mediated through suppression of herpes.
Notably, results of in-vitro studies 34, 35 suggest that aciclovir could directly inhibit HIV-1 replication, possibly through kinases from other ubiquitous herpes viruses (eg, human herpes virus 6). Findings from an in vitro study 35 with high-dose aciclovir showed selection of an uncommon HIV-1 mutation-V75I. However, the 0·25 log 10 average decreased plasma HIV-1 concentrations observed in our study 19 persisted during 24 months of follow-up without an HIV-1 plasma RNA rebound, contrary to what might be expected from selection of resistant variants. In future investigations, we will assess incidence of HIV-1 mutations in the aciclovir versus placebo groups during follow-up to assess specifi c mechanisms underlying HIV-1 plasma RNA reductions.
Aciclovir has a much lower frequency of adverse eff ects than do many antiretroviral therapy regimens that are used in resource-poor settings. We identifi ed no serious adverse events associated with aciclovir. 19 This drug was well tolerated, which probably contributed to the high adherence in our study. Additionally, the absence of a need for specifi c laboratory monitoring for aciclovir toxicity during herpes suppression is especially important when laboratory infrastructure for monitoring and access to care are restricted. Our selection of a standard dose of aciclovir (similar to valaciclovir 500 mg twice daily 36 ) was based on effi cacy of this dose in reduction of frequency of symptomatic genital ulcer disease and asymptomatic reactivation of type 2 genital herpes in dually infected people, 37,38 a well-documented safety profi le, generic availability, and a relatively low cost. A meta-analysis 39 of several small studies of highdose (≥3200 mg per day) aciclovir for suppression of herpes virus type 2 in conjunction with mononucleoside or dual nucleoside antiretroviral therapy identifi ed a similar magnitude of eff ect on HIV-1 associated mortality (HR 0·78, 95% CI 0·65-0·93) to that reported in our study. Whether increased doses of herpes suppressive therapy have a heightened eff ect on HIV-1 plasma concentrations and disease progression needs to be investigated.
Further investigation is needed to determine costeff ectiveness and clinical and public health eff ects of suppression of herpes simplex virus 2 to slow HIV-1 disease progression until dually infected people reach guidelines for antiretroviral therapy initiation. Table 4 shows our summary results in the context of other nonantiretroviral therapy biomedical interventions that were investigated for their eff ect on measures of HIV-1 disease progression. Trimethoprim-sulfamethoxazole prophylaxis and multivitamins in people infected with HIV-1 have become standard practice in many resourcepoor settings, on the basis of trials showing a reduction in HIV-1 associated mortality of about 45% vitamins. However, such non-antiretroviral therapy interventions to reduce HIV-1 disease progression were undertaken in the era before combination antiretroviral therapy was widely available, and thus included followup of people with advanced disease. Furthermore, in subgroup analyses, 43 trimethoprim-sulfamethoxazole had greatest effi cacy in individuals with CD4 cell counts fewer than 200 cells per μL or symptoms of advanced immunosuppression. By contrast, we identifi ed that suppression of type 2 herpes virus delayed HIV-1 disease progression in a low-resource setting in men and women with a wide range of ages and CD4 cell counts of 250 cells per μL or higher at enrolment.
The International AIDS Society-USA Panel 28 revised recom mendations to start antiretroviral therapy at CD4 cell counts of fewer than 350 cells per μL in some settings. Early initiation of antiretroviral therapy on will probably have a greater eff ect on disease progression than we noted with aciclovir in this study, and might have an ancillary benefi t of reduction of HIV-1 transmission. However, availability of resources are insuffi cient in many settings to provide this therapy even to those with CD4 counts of fewer than 200 cells per μL. 46 Furthermore, in view of the interest in identifi cation of interventions for people with high counts, we need further detailed investigation of suppression of herpes simplex virus type 2 in people with counts of more than 500 cells per μL. Results of a cost-eff ectiveness analysis 47, 48 showed that herpes virus type 2 suppression meets the World Development Report cost-eff ectiveness threshold ($1000 per life-year gained) at the lowest available pricing for generic aciclovir ($25 per year for twice daily aciclovir 400 mg tablets). However, the local pricing of aciclovir varies widely, and can exceed the international reference price by 6-10-fold in sub-Saharan Africa. 49 Eff orts are needed to improve drug procurement, distribution, and access throughout sub-Saharan Africa for aciclovir to have a maximum eff ect on the HIV-1 epidemic. Mathematical modelling could be useful to defi ne how to best use herpes simplex virus 2 suppression to aff ect the HIV-1 epidemic. Such modelling could be used to quantify the benefi ts, costs, and potential eff ect of implementation of such suppression or other non-antiretroviral therapy strategies compared with previous antiretroviral therapy initiation to delay HIV-1 disease progression.
One limitation of our study was the low frequency of diagnostic testing and autopsies to inform the causes of death. Furthermore, although most participants were given antiretrovirals at CD4 counts of 200 cells per μL or fewer, reasons for therapy initiation at counts higher than 200 cells per μL were not recorded because antiretroviral care was generally provided outside the study clinics. Trimethoprim-sulfame thoxazole prophylaxis data were also not gathered at all sites; however, at fi ve sites where this information was recorded, participants reported trimethoprim-sulfamethoxazole use at 73% of follow-up visits, and this use did not diff er by treatment group (data not shown). Finally, although fi ndings of studies suggest HIV-1 disease progression might diff er by HIV-1 subtype, 50 subtype data are not available for our cohort and will be assessed in future analyses.
We have shown that aciclovir for herpes simplex virus type 2 suppression in people dually infected with HIV-1 and herpes type 2 with CD4 cell counts higher than 250 cells per μL who are not taking antiretroviral therapy can modestly reduce risk of HIV-1 disease progression. Further investigation is needed to establish if suppression of this herpes virus has a role in HIV-1 treatment for people not eligible for antiretroviral therapy.
Contributors
The core protocol team (CC, AW, JRL, JMB, LC, AM, and JPH) designed the study, and JPH and KT undertook the primary data analysis. All investigators contributed to gathering of data, reviewed report drafts, and approved the fi nal manuscript. JRL, JMB, and CC wrote the fi rst draft.
Confl icts of interest
CC has received research grant support from GlaxoSmithKline (GSK), which did not include salary support, and has served on an advisory board for this company; AW has received grant support from Astellas, GSK, and Antigenics, and has been a consultant for Astellas and Aicuris; KF has received research grant funding from Astellas Pharma USA and GSK; LC is a consultant for AiCuris and GenPhar and is the head of the Scientifi c Advisory Board of Immune Design, receiving fi nancial remuneration for this position, including equity shares that are less than 1% ownership. University of Washington Virology Division Laboratories have received grant funding from GSK and Novartis to undertake herpes simplex virus serological assays and PCR assays for studies funded by these companies; LC directs these laboratories, but receives no salary support from these grants.
